Events and Teleconferences

Event Locator

Teva Neuroscience is committed to providing informative and in-person educational seminars about relapsing MS (RMS) across the country. These seminars are open to all individuals impacted by MS. We hope that you can attend local events and programs that take place in your area.

Simply select a state or enter a ZIP code below to find an event near you.

OR

Teleconferences

Join us for educational teleconferences about RMS brought to you by Teva Neuroscience. During these discussions, we address a variety of topics and issues that are relevant to the MS community. The teleconferences are hosted by leading MS experts and include a live question and answer session. The MS experts have been compensated by Teva.

Ongoing Teleconferences:

Call 1-800-823-1880 today to set up a reminder call for the teleconference. Please note that no reservation is required.

February 27, 2018 – 8:00 p.m. ETFebruary 28, 2018 – 9:00 p.m. ET

Speaker: Dr. Mirla AvilaPatient Advocate: SueAnn H.

Invisible Symptoms: Fatigue and Cognitive
Dysfunction in MSMS symptoms are varied and unpredictable, especially,
when they’re not visible. Learn strategies to help manage
cognition and fatigue in this series.

March 27, 2018 – 8:00 p.m. ETMarch 28, 2018 – 9:00 p.m. ET

Speaker: Dr. Lucas McCarthyPatient Advocate: Jeffrey S.

Wellness with RMSIn this session, we’ll share ideas for gaining an
understanding of overall wellness in RMS that
include, common RMS symptoms and management
strategies, building your RMS support network,
empowering yourself to seek help for emotional
changes and more!

Shared Solutions® is my partner in managing MS. Their live events and teleconferences have been an ongoing part of maintaining strength and confidence during the past 13 years.

TEST YOUR KNOWLEDGE

Important Safety Information

Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol. Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and do not require specific treatment.

Use

COPAXONE® (glatiramer acetate injection) is prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS).

Important Safety Information

Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.

Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.

A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.

The most common side effects in studies of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Use

COPAXONE® (glatiramer acetate injection) is prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis (MS).

Important Safety Information

Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol.

Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.

Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.

A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.

The most common side effects in studies of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

†Applies only to daily COPAXONE® 20 mg. Certain limits and restrictions apply.COPAXONE Co-pay Solutions® Program Rules for COPAXONE® (Glatiramer Acetate Injection) 20 mg—Patient Eligibility, Terms and Conditions: Valid only for qualified patients with a valid prescription for COPAXONE® (glatiramer acetate injection) 20 mg/mL. No substitutions permitted. This card is valid only for patients with commercial insurance coverage for COPAXONE® 20 mg/mL. This card is not valid for prescriptions paid for in part or in full by any state or federally funded program, including but not limited to, Medicare or Medicaid, Medigap, VA, DoD, TRICARE, the Puerto Rico Government Health Insurance Plan or by private health insurance plans or programs which reimburse you for the entire costs of your prescription drugs. This card is not valid for patients who are Medicare eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (i.e., you are eligible for Medicare Part D but receive a prescription drug benefit through a former employer). Your discount with this card is valid to reduce your co-pay down to $35 with a maximum benefit of $2,500 per 30 day prescription/refill per calendar month. The total annual benefit amount is $12,000 per year. Patient is responsible for costs above these amounts. Discount is available on up to 13 prescription/refills for COPAXONE®. Offer expires on 12/31/18. Your acceptance of this offer must be consistent with the terms of any drug benefit provided by a health insurer, health plan, or other third-party payer, and you agree to report acceptance of this offer to your health insurer, health plan, or third-party payer as may be required. Offer limited to one card per person and may not be used with any other discount, coupon or offer. Offer is not transferable. It is illegal to sell, purchase, trade or counterfeit this card. This card is not health insurance. This card is the property of Teva Neuroscience, Inc. and must be returned upon request. Offer valid only in the United States or the Commonwealth of Puerto Rico at participating retail, mail order and specialty pharmacies. For California residents, this card is not valid unless you have satisfied any prior authorization or step therapy requirements imposed by your insurer and, by using this card, you acknowledge that you have met these requirements. Void in Massachusetts and in any other state where prohibited by law, taxed, or restricted. Teva Neuroscience, Inc. reserves the right to change, rescind, revoke, or discontinue this offer at any time without notice.

††Applies only to 3-times-a-week COPAXONE® 40 mg. Certain limits and restrictions apply.COPAXONE Co-pay Solutions® Program Rules for COPAXONE® (Glatiramer Acetate Injection) 40 mg—Patient Eligibility, Terms and Conditions: Valid only for qualified patients with a valid prescription for COPAXONE® 40 mg/mL. No substitutions permitted. This card is valid only for patients with commercial insurance coverage for COPAXONE® 40 mg/mL. This card is not valid for prescriptions paid for in part or in full by any state or federally funded program, including but not limited to, Medicare or Medicaid, Medigap, VA, DoD, TRICARE, the Puerto Rico Government Health Insurance Plan or by private health insurance plans or programs which reimburse you for the entire costs of your prescription drugs. This card is not valid for patients who are Medicare eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees (i.e., you are eligible for Medicare Part D but receive a prescription drug benefit through a former employer). Your discount with this card is valid to reduce your co-pay down to $0 with a maximum benefit of $5,000 per 28 day prescription/refill in January and February and $2,500 per 28 day prescription/refill March through December. The total annual benefit amount is $12,000 per year. Patient is responsible for costs above these amounts. Discount is available on up to 14 prescription/refills for COPAXONE®. Offer expires on 12/31/18. Your acceptance of this offer must be consistent with the terms of any drug benefit provided by a health insurer, health plan, or other third-party payer, and you agree to report acceptance of this offer to your health insurer, health plan, or third-party payer as may be required. Offer limited to one card per person and may not be used with any other discount, coupon or offer. Offer is not transferable. It is illegal to sell, purchase, trade or counterfeit this card. This card is not health insurance. This card is the property of Teva Neuroscience, Inc. and must be returned upon request. Offer valid only in the United States or the Commonwealth of Puerto Rico at participating retail, mail order and specialty pharmacies. For California residents, this card is not valid unless you have satisfied any prior authorization or step therapy requirements imposed by your insurer and, by using this card, you acknowledge that you have met these requirements. Void in Massachusetts and in any other state where prohibited by law, taxed, or restricted. Teva Neuroscience, Inc. reserves the right to change, rescind, revoke, or discontinue this offer at any time without notice.

A condition in which the body's immune system mistakenly attacks its own tissue

The long, threadlike part of a neuron, or nerve cell, along which nerve signals are conducted

A term used to describe the brain and the spinal cord; the part of the body affected by multiple sclerosis

A clear fluid that circulates in the space surrounding the brain and spinal cord

A first neurologic episode that lasts at least 24 hours and is caused by inflammation/demyelination in 1 or more sites in the central nervous system

A degenerative process that erodes away the myelin sheath that normally protects nerve fibers. Demyelination exposes these fibers and appears to cause problems in nerve impulse conduction that may affect many physical systems

A strict method of conducting a clinical study that helps reduce the possibility of bias (unfair influence). In this type of study, health care providers and participants are “blinded,” meaning neither group knows what drug regimen each participant is taking

A testing method that measures electrical activity in the central nervous system

One of the most widely used rating systems for determining the ability level of people with RRMS. The EDSS measures changes in a person's physical ability in one-half step increments on a scale beginning with 0.0 and worsening to a level of 10.0. People with an EDSS level of 0.0 to 5.0 were included in the pivotal studies. Here are some of the scores from the EDSS and what they represent:EDSS (up to 6.0)76.0 = Assistance needed to walk (single cane, crutch, or brace)2.0-5.5 = Able to walk without assistance (various levels of disability present)1.0-1.5 = No disability (some abnormal signs on the neurological exam)0.0 = Normal neurological exam

One of the most complex biological systems, made up of an advanced network of cells, tissues, and organs that work together to provide the body with a natural system of defenses

The measurement(s) taken during the last follow-up with a participant in a study

In multiple sclerosis, a damaged area in the brain or spinal cord caused by demyelination (also called plaque or sclerosis)

A diagnostic procedure employing a special scanner to obtain detailed images of a specific area of the body, such as the brain or spinal cord. Two scans traditionally used are T1 (sometimes also reported as gadolinium enhanced, GD) and T2. T1 can use a dye that allows the MRI to show areas of active inflammation. T2 images are helpful in providing information about disease burden or lesion load2

A clinical study that takes place at more than 1 medical center or clinic. Potential benefits of multicenter studies include a larger number of participants, different geographic locations, inclusion of various ethnic groups, and the ability to compare results among different medical centers—all of which help remove bias from the study

A disease that attacks the central nervous system. With MS, the immune system creates swelling and causes damage to the nerve coating (called myelin) that protects the nerve fibers in the brain and spinal cord. This damage prevents nerve cells from communicating properly to relay signals to and from other parts of the body

A medical doctor (or physician) who specializes in conditions that affect the nervous system, such as multiple sclerosis, epilepsy, or Parkinson's disease

The basic nerve cell of the central nervous system

Before launching a larger-scale clinical study, a pilot study may be conducted to ensure that the logistics, management, methods, and ideas behind an area of research is feasible. Pilot studies can also be used to test different dosages of, modes of administration for, and levels of compliance with a therapy

A controlled study to evaluate the safety and effectiveness of a drug in people who have the disease or condition to be treated. These studies usually represent the most rigorous demonstration of the drug's effectiveness and safety, and are the basis for filing with the FDA for approval to treat the disease

An inactive substance that looks like the active drug and helps determine the effectiveness of a drug by providing a basis for comparison

The main goal of a clinical study. This goal must be met in order for the study to be considered successful

A method of conducting a clinical study in which participants are randomly chosen to take either one drug regimen or another. This method reduces the bias that can negatively affect the validity of medical research

A worsening of MS symptoms or an appearance of new symptoms (also called attack, exacerbation, or flare-up)

The most common form of MS, affecting approximately 85% of all newly diagnosed people. RRMS is characterized by relapses that are usually followed by partial or complete recovery

Relapsing forms of MS are considered to be inclusive of relapsing-remitting MS (RRMS) and clinically isolated syndrome (CIS). RRMS is the most common form of MS, affecting approximately 85% of all newly diagnosed people. RRMS is characterized by relapses that are usually followed by partial or complete recovery. CIS is a first neurologic episode that lasts at least 24 hours and is caused by inflammation/demyelination in 1 or more sites in the central nervous system.

Hardening of tissue. In MS, sclerosis is the body's replacement of lost myelin around central nervous system cells with scar tissue (also called lesion or plaque). The plural of this word is “scleroses”

Other important goals for measuring a treatment's effectiveness or safety in a clinical study

An injection with a shorter needle given into the fatty layer just under the skin

One type of protective white blood cell that travels throughout the bloodstream looking for viruses, bacteria, fungal infections, and tumor cells. T cells play an important role in protecting the body